Tumour targeting of humanised cross-linked divalent-fab′ antibody fragments: a clinical phase I/II study
Joanne L. Casey(Roland Hill (United Kingdom)), Richard H. J. Beǵent(The Royal Free Hospital), Lorraine Skelton, A J Green(The Royal Free Hospital), Mark Napier(The Royal Free Hospital), Laura Hope‐Stone(The Royal Free Hospital), Neil Weir, Geoffrey Yarranton, L Chaplin, David J. King(Regulus Therapeutics (United States)), RB Pedley(The Royal Free Hospital)
Cited by 43
Related Papers
High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker
|Nature Biotechnology|1992|465
A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody
|Molecular Immunology|1993|243
Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells.
|PubMed|1996|212
Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3
|Protein Engineering Design and Selection|1994|122